Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response.

Autor: Jang SO; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea., Lee JH; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea., Chung YJ; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea., Oh HS; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea., Shin M; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea., Kim SO; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea., Hong SP; R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea. Electronic address: sunphong@genematrix.net.
Jazyk: angličtina
Zdroj: Virology [Virology] 2024 Dec; Vol. 600, pp. 110243. Date of Electronic Publication: 2024 Sep 16.
DOI: 10.1016/j.virol.2024.110243
Abstrakt: Herpes zoster (HZ), or shingles, is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the sensory ganglia until immunity wanes with age. The representative HZ vaccine, Shingrix is efficacious but causes side effects due to vaccine adjuvants. Therefore, the development of highly efficacious vaccines with minimal side effects is required. We developed chimeric adenovirus vector (ChimAd)-based HZ vaccine candidates encoding the VZV glycoprotein E (gE). These candidates include ChimAd-tPAgE, in which the signal peptide is replaced with tissue plasminogen activator (tPA), and ChimAd-WTgE, which retains the original signal peptide. C57BL/6 mice were immunized with VZV-vaccine candidates, and cellular and humoral immune responses were evaluated using interferon-γ ELISPOT and ELISA. The ChimAd-based HZ vaccines induced high levels of gE-specific antibodies and cell-mediated immunity. ChimAd-tPAgE (optimal dose: 1 × 10 7 IFU) elicited a more robust gE-specific T-cell response than Shingrix and Zostavax, showing potential as HZ prophylactic vaccines.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.Sun Ok Jang, Jae Hyun Lee, Yong-Ju Chung, Hyun-Seok Oh, Myeongcheol Shin, Soo-Ok Kim, Sun Pyo Hong reports financial support was provided by Ministry of Food and Drug Safety. Kim, S. HS, Kim S, Jang S, Kim H, Lee S has patent licensed to GeneMatrix, Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: